Effect of Sanhuang Yinchi Decoction in Preventing Acute Liver Injury by HMGB1 Signaling Pathway
10.13422/j.cnki.syfjx.20190603
- VernacularTitle: 三黄茵赤汤通过调节HMGB1信号通路防治急性小鼠肝损伤
- Author:
Jia-yang WU
1
;
Jing-yu QUAN
1
;
Yan-xin ZHOU
1
;
Yi-meng CHEN
1
;
Jian-xin DIAO
1
Author Information
1. School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, China
- Publication Type:Research Article
- Keywords:
acute liver injury;
Sanhuang Yinchi decoction;
high mobility group box1(HMGB1);
apoptosis;
Yinchenhao Tang
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2019;25(6):58-64
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effect and mechanism of Sanhuang Yinchi decoction (SHYCD) in preventing carbon tetrachloride (CCl4)-induced acute liver injury by regulating high mobility group box1(HMGB1) signaling pathway. Method:A total of 48 KM mice were randomly divided into blank control group, model group, low, middle and high-dose SHYCD groups and positive control group. The model of acute liver injury induced by CCl4 in mice was established. The low, middle and high-dose SHYCD groups were intragastrically administered with drugs (16, 32, 48 g·kg-1·d-1) respectively, and the positive control group was given cell growth stimulating hormone (20 mg·kg-1·d-1) through intraperitoneal injection. Pathological changes of mouse liver tissue sections were observed by hematoxylin-eosin staining (HE); relevant enzyme kits were used to determine liver function indexes in mice serum-alanine aminotransferase (AST) and aspartate aminotransferase (ALT); the expression level of interleukin-6 (IL-6) in mouse serum was determined by enzyme-linked immunosorbent assay (ELISA); Western blot was used to detect the expressions of high mobility group box-1(HMGB1), cysteine aspartic acid protease(Caspase-3), apoptosis-related molecules B cell lymphoma(Bcl-2), Bcl-2 associated x protein(Bax), and Toll-like receptor 4 (TLR4). Result:Compared with the normal group, the model group significantly increased serum AST, ALT (P<0.05) and IL-6 levels (P<0.05) and expressions of HMGB1, TLR4 and Caspase-3 (P<0.05), and down-regulated Bcl-2/Bax ratio (P<0.05) in liver tissue; compared with the model group, SHYCD can effectively alleviate the pathological damage of liver in mice, reduce serum AST and ALT levels and expressions of IL-6, HMGB1, TLR4 and Caspase-3 protein in liver homogenate (P< 0.05), and increased the ratio of Bcl-2/Bax (P<0.05) in a dose-dependent manner. Conclusion:SHYCD can prevent liver injury by regulating HMGB1/TLR4/NF-κB signaling pathway, reducing cellular inflammatory response and inhibiting apoptosis, so as to prevent acute liver injury in mice. This indicates that HMGB1 may become a new target to prevent acute liver injury.
